{"": [116, 1300, 0], "Introduction": [1301, 5934, 0], "The DA-D4 point-of-care test (POCT) for COVID-19 serology": [5944, 9622, 0], "Analytical validation of the DA-D4 POCT using simulated samples": [9623, 13469, 0], "Clinical validation of the DA-D4 POCT": [13470, 19320, 0], "Monitoring antibody levels longitudinally": [19321, 21801, 0], "Concordance with neutralizing antibody titers": [21802, 23338, 0], "Profiling prognostic biomarkers concurrent with serological testing": [23339, 27484, 0], "Results": [5935, 27484, 1], "Discussion": [27485, 39428, 0], "DA-D4 assay": [39452, 41418, 0], "Fabrication and analytical testing of open format DA-D4": [41419, 42151, 0], "Fabrication and analytical testing of microfluidic DA-D4": [42152, 44595, 0], "Clinical testing of microfluidic DA-D4": [44596, 45062, 0], "D4Scope fabrication and operation": [45063, 47212, 0], "Patient samples": [47213, 48744, 0], "Live SARS-CoV-2 Microneutralization assay (MN)": [48745, 49562, 0], "IP-10 experiments": [49563, 50515, 0], "Statistical analysis": [50516, 50978, 0], "Materials and methods": [39429, 50978, 1], "Supplementary Material": [50979, 51005, 0]}